Dearborn Partners LLC Gilead Sciences, Inc. Transaction History

Dearborn Partners LLC

$2.42 Billion
Q3 2024

A detailed history of Dearborn Partners LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Dearborn Partners LLC holds 319,125 shares of GILD stock, worth $29.5 Million. This represents 1.11% of its overall portfolio holdings.

Number of Shares

319,125

Previous 331,079 3.61%

Holding current value

$29.5 Million

Previous $22.7 Million 17.76%

% of portfolio

1.11%

Previous 0.99%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$66.59 - $83.99 $796,016 - $1 Million	-11,954 Reduced 3.61%	319,125 $26.7 Million
Q2 2024 Jul 26, 2024	SELL	$63.15 - $72.88 $207,258 - $239,192	-3,282 Reduced 0.98%	331,079 $22.7 Million
Q1 2024 May 08, 2024	SELL	$71.58 - $87.29 $7.36 Million - $8.98 Million	-102,882 Reduced 23.53%	334,361 $24.5 Million
Q4 2023 Jan 26, 2024	SELL	$73.27 - $83.09 $854,108 - $968,580	-11,657 Reduced 2.6%	437,243 $35.4 Million
Q3 2023 Nov 01, 2023	BUY	$73.94 - $80.67 $332,582 - $362,853	4,498 Added 1.01%	448,900 $33.6 Million
Q2 2023 Aug 03, 2023	SELL	$76.01 - $86.7 $562,397 - $641,493	-7,399 Reduced 1.64%	444,402 $34.3 Million
Q1 2023 May 04, 2023	SELL	$77.31 - $88.08 $54,117 - $61,656	-700 Reduced 0.15%	451,801 $37.5 Million
Q4 2022 Feb 02, 2023	SELL	$62.32 - $89.47 $115,042 - $165,161	-1,846 Reduced 0.41%	452,501 $38.8 Million
Q3 2022 Oct 25, 2022	BUY	$59.54 - $68.01 $714 - $816	12 Added 0.0%	454,347 $28 Million
Q2 2022 Jul 20, 2022	BUY	$57.72 - $65.01 $201,096 - $226,494	3,484 Added 0.77%	454,335 $28.1 Million
Q1 2022 May 04, 2022	BUY	$57.92 - $72.58 $672,509 - $842,726	11,611 Added 2.64%	450,851 $26.8 Million
Q4 2021 Jan 28, 2022	SELL	$64.88 - $73.64 $105,300 - $119,517	-1,623 Reduced 0.37%	439,240 $31.9 Million
Q3 2021 Oct 27, 2021	BUY	$67.69 - $73.03 $139,915 - $150,953	2,067 Added 0.47%	440,863 $30.8 Million
Q2 2021 Jul 26, 2021	BUY	$63.47 - $69.35 $148,710 - $162,487	2,343 Added 0.54%	438,796 $30.2 Million
Q1 2021 Apr 29, 2021	BUY	$60.0 - $68.46 $1.33 Million - $1.52 Million	22,217 Added 5.36%	436,453 $28.2 Million
Q4 2020 Jan 27, 2021	BUY	$56.65 - $64.55 $173,632 - $197,845	3,065 Added 0.75%	414,236 $24.1 Million
Q3 2020 Oct 20, 2020	SELL	$62.1 - $78.08 $26,144 - $32,871	-421 Reduced 0.1%	411,171 $26 Million
Q2 2020 Jul 30, 2020	BUY	$72.34 - $84.0 $4.26 Million - $4.95 Million	58,904 Added 16.7%	411,592 $31.7 Million
Q1 2020 May 11, 2020	BUY	$62.63 - $80.22 $597,364 - $765,138	9,538 Added 2.78%	352,688 $26.4 Million
Q4 2019 Jan 28, 2020	BUY	$61.62 - $67.78 $1.69 Million - $1.85 Million	27,363 Added 8.67%	343,150 $22.3 Million
Q3 2019 Oct 29, 2019	BUY	$62.51 - $69.0 $1.87 Million - $2.06 Million	29,926 Added 10.47%	315,787 $20 Million
Q2 2019 Jul 29, 2019	BUY	$61.87 - $69.38 $636,889 - $714,197	10,294 Added 3.74%	285,861 $19.3 Million
Q1 2019 May 01, 2019	BUY	$62.53 - $70.05 $1.06 Million - $1.19 Million	16,984 Added 6.57%	275,567 $17.9 Million
Q4 2018 Feb 04, 2019	SELL	$60.54 - $79.0 $37,716 - $49,217	-623 Reduced 0.24%	258,583 $16.2 Million
Q3 2018 Oct 24, 2018	BUY	$71.28 - $78.92 $5.07 Million - $5.61 Million	71,145 Added 37.83%	259,206 $20 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $327,773 - $382,335	-5,052 Reduced 2.62%	188,061 $13.3 Million
Q1 2018 May 01, 2018	SELL	$72.84 - $88.8 $343,440 - $418,692	-4,715 Reduced 2.38%	193,113 $14.6 Million
Q4 2017 Feb 02, 2018	SELL	$71.15 - $83.52 $503,599 - $591,154	-7,078 Reduced 3.45%	197,828 $14.2 Million
Q3 2017 Nov 13, 2017	SELL	$72.11 - $85.47 $888,467 - $1.05 Million	-12,321 Reduced 5.67%	204,906 $16.6 Million
Q2 2017 Aug 09, 2017	BUY	N/A	217,227	217,227 $15.4 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dearborn Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dearborn Partners LLC with notifications on news.

Account

Dearborn Partners LLC Gilead Sciences, Inc. Transaction History